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ABSTRACT
TAR DNA binding protein-43 (TDP-43) is found in
ubiquitinated inclusions (UBIs) in some frontotemporal
dementias (FTD-U). One form of FTD-U, due to mutations
in the valosin containing protein (VCP) gene, occurs with
an inclusion body myopathy (IBMPFD). Since IBMPFD
brain has TDP-43 in UBIs, we looked for TDP-43 inclusions
in IBMPFD muscle. In normal muscle, TDP-43 is present in
nuclei. In IBMPFD muscle, TDP-43 is additionally present
as large inclusions within UBIs in muscle cytoplasm. TDP-
43 inclusions were also found in 78% of sporadic inclusion
body myositis (sIBM) muscles. In IBMPFD and sIBM
muscle, TDP-43 migrated with an additional band on
immunoblot similar to that reported in FTD-U brains. This
study adds sIBM and hereditary inclusion body myopa-
thies to the growing list of TDP-43 positive inclusion
diseases.
TAR DNA binding protein-43 (TDP-43) is one
component of the ubiquitinated inclusions in the
brains of patients with frontotemporal dementias
(FTD-U) and amyotrophic lateral sclerosis (ALS).1
A phosphorylated form of TDP-43 was also
identified to be more prevalent specifically in
FTD-U tissue.1 More recently, missense mutations
have been identified in TOP-43 that cosegregate
with autosomal dominantly inherited ALS.2–5 Little
is known about the function of TDP-43. It is a
ubiquitously expressed, highly conserved nuclear
protein that may be a transcription repressor or
activator of exon skipping as well as a scaffold for
nuclear bodies through interactions with survival
motor neuron protein.1 The significance of TDP-43
accumulation and phosphorylation is currently
unclear but may relate to ubiquitin proteasome
system (UPS) dysfunction. One rare form of FTD-
U, inclusion body myopathy (IBM), Paget’s disease
of the bone and frontotemporal dementia
(IBMPFD) has ubiquitinated and TDP-43 positive
inclusions in affected neurons6 7 while IBMPFD
muscle contains rimmed vacuoles and ubiquiti-
nated inclusions (UBIs) consistent with an IBM.8
The pathogenesis of IBM and the more common
sporadic inclusion body myositis (sIBM) is unknown
but may also be due to UPS dysfunction.9 Affected
muscle has UBIs that contain proteins, such as b-
amyloid and phosphorylated tau, known to aggre-
gate in CNS degenerative disorders.10 11 This has led
to the suggestion that sIBM is related pathophysio-
logically to neurodegenerative diseases. It is not
known whether TDP-43 is a component of the
inclusions in IBMPFD and sIBM muscle tissue. We
evaluated the localisation of TDP-43 in normal,
IBMPFD and sIBM skeletal muscle tissue.
METHODS
Patients with sIBM had typical patterns of muscle
weakness on physical examination, an abnormal
EMG with myopathic motor units and spontaneous
activity, and a muscle biopsy with myopathic
changes, rimmed vacuoles within muscle fibres and
endomysial inflammation with focal invasion of
muscle fibres.12 Five patients with IBMPFD and
missense mutations in the p97/valosin containing
protein (VCP) gene (four with R155H and one with
N387H)13 were participants in the IRB approved
study. All muscle biopsies were processed and
evaluated in the Washington University
Neuromuscular Laboratory. Cryostat sections of
rapidly frozen muscle were processed for muscle
histochemistry and immunocytochemistry in our
standard fashion.8 13 The presence of vacuoles was
evaluated via routine histochemical methods, such as
haematoxylin and eosin or modified Gomori–tri-
chrome stains. Immunocytochemistry for each anti-
body was performed on tissue from patients and
compared with normal tissue controls processed
simultaneously. Primary antibodies used in this study
were directed against CD8 (clone M7103), phos-
phorylated neurofilaments or other phosphorylated
epitopes (SMI-31; Covance, Berkley, California,
USA), FK2 antibody to ubiquitinated proteins
(PW8810-0500; BioMol, Plymouth Meeting,
Pennsylvania, USA), TDP-43 antibodies: rabbit poly-
clonal antibody (ProteinTech Antibody Group,
Chicago, Illinois, USA) and mouse monoclonal anti-
body 2E2-D3 (Abnova, Taipei, Taiwan). Double
labelling immunofluorescence was performed as
previously described using Alexa Fluor 488 and 594
conjugated secondary antibodies (Molecular Probes;
Eugene, Oregon, USA). Immunoperoxidase was
performed as previously described using peroxidase
conjugated secondary antibodies (Sigma, St Louis,
Missouri, USA). The specificity of TDP-43 immu-
nostaining was confirmed with two different com-
mercial antibodies and incubation with secondary
antibody alone (either fluorescent or peroxidase
conjugated). Immunoblots were performed as pre-
viously described.14
RESULTS
In four normal muscle biopsies, TDP-43 was
localised within scattered myonuclei with no
evidence of sarcoplasmic staining (fig 1A). In
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contrast, all IBMPFD muscle tissue had large peripherally based
TDP-43 positive sarcoplasmic inclusions that did not localise to
myonuclei (fig 1B, 1C). These inclusions consistently colocalised
with FK2, an antibody that recognises ubiquitinated proteins
(fig 1D) and in some cases with other proteins known to
aggregate. SMI-31 binding was less prominent than TDP-43 in
IBMPFD muscle tissue (fig 1E).
A distinctively different pattern of TDP-43 immunostaining
was seen in 21 of 27 sIBM muscle. TDP-43 immunostained
multiple small sarcoplasmic aggregates, most commonly in
small angular muscle fibres (fig 2A). These inclusions did not
colocalise with myonuclei. TDP-43 was also present in debris
surrounding some rimmed vacuoles (fig 2A). The TDP-43
inclusions in sIBM were usually ubiquitin negative (fig 2B),
but occasionally colocalised with FK2. TDP-43 also colocalised
with T cells at sites of inflammatory infiltrates (fig 2C).
In contrast with sIBM, TDP-43 positive inclusions were found
in only 1 of 12 steroid responsive polymyositis patient
biopsies.
Immunoblots of normal, IBMPFD and sIBM patient tissue
with an antibody to TDP-43 demonstrated an increase in TDP-
43 immunoreactivity present at 43 kDa as well as a higher
migrating band similar to the phosphorylated form seen in FTD-U
patient tissue (fig 2D).
DISCUSSION
Disruptions in the UPS may be associated with the pathogenesis
of several degenerative disorders. In particular, IBM muscle and
FTD-U brain have UBIs that contain aggregated proteins.
However, the principal molecular constituents of the UBIs seen
in these diseases have been incompletely defined. Recent studies
have identified TDP-43 as a component of the UBIs in FTD-U,
including IBMPFD, and ALS brain tissue.1 7 As IBMPFD muscle
also has UBIs, we examined the localisation of TDP-43 in
normal, sIBM and IBMPFD patient skeletal muscle. We found
that TDP-43 localised to myonuclei in normal muscle but, in
IBMPFD and sIBM muscle, TDP-43 was additionally present as
sarcoplasmic inclusions. This is associated with an increase in
Figure 1 (A) Normal muscle
immunostained with anti-TAR DNA
binding protein-43 (TDP-43) antibody and
counterstained with DAPI to allow
visualisation of nuclei. The figure is an
overlay of anti-TDP-43 and DAPI images.
Arrows denote blue nuclei with TDP-43
(red dots) in scattered myonuclei.
(B) Inclusion body myopathy, Paget’s
disease of the bone and frontotemporal
dementia (IBMPFD) tissue from patients
immunostained with anti-TDP-43 (brown)
and counterstained with Congo red to
allow visualisation of nuclei and
myofibres. Arrows denote large
inclusions, some of which are peripherally
based. (C) Overlay of anti-TDP-43
(orange) and DAPI (blue) of IBMPFD
patient tissue. Note that large peripheral
inclusions do not localise within nuclei
(arrows). (D) IBMPFD patient tissue co-
immunostained with anti-TDP-43 (red)
and FK2 (green). Note that TDP-43
inclusions colocalise with FK2
(ubiquitinated proteins) (arrows). (E)
IBMPFD patient tissue co-immunostained
with anti-TDP-43 (red) and SMI-31, an
antibody against phosphorylated tau
epitopes (green). Note that some TDP-43
inclusions colocalise with SMI31 (closed
arrows) and others do not (open arrows).
Short report
J Neurol Neurosurg Psychiatry 2008;79:1186–1189. doi:10.1136/jnnp.2007.131334 1187
 group.bmj.com on November 17, 2010 - Published by jnnp.bmj.comDownloaded from 
TDP-43 protein levels as well as a higher molecular weight band
seen in sIBM and IBMPFD patient muscle tissue via immuno-
blot when compared with normal patient tissue. A similar
higher molecular weight band was identified as phosphorylated
TDP-43 in patients with FTD-U and ALS.1 Whether the band
seen in IBMPFD and sIBM muscle tissue is the same or another
post-translationally modified form (ie, ubiquitinated) is not
known.
TDP-43 inclusions were present in 100% of IBMPFD and 78%
of sIBM patient muscle biopsies, while 0% of normal muscle and
8% of steroid responsive polymyositis patient muscle biopsies
had similar TDP-43 inclusions. This suggests that TDP-43
immunohistochemistry may be helpful in confirming the
diagnosis of sIBM. At present, the most reliable antibody
marker for the diagnosis of sIBM is SMI-31 (an antibody against
phosphorylated tau epitopes) which is not present in all sIBM
biopsies and found in other diseased muscle tissue.15 For
example, in our hands, SMI-31 positive aggregates are present
in 66% of sIBM patients compared with 17% of steroid
responsive polymyositis patients (unpublished observations).
It is notable that the TDP-43 immunostaining pattern was
different when comparing sIBM and IBMPFD muscle. sIBM had
small punctuate TDP-43 positive inclusions throughout the
sarcoplasm that occasionally colocalised with ubiquitin.
IBMPFD muscle had large peripherally based TDP-43 positive
inclusions that always colocalised with ubiquitin. Both sIBM
and IBMPFD patient muscle had evidence of a higher molecular
weight TDP-43 species on immunoblot.
Our findings in skeletal muscle are similar to those found in
CNS disease.1 TDP-43 inclusions in FTD-U and ALS are
cytoplasmic, similar to the predominantly sarcoplasmic inclu-
sions in IBM muscle. The presence of ubiquitinated TDP-43 in
disparate tissues (ie, IBMPFD muscle and brain) in which the
only commonality is mutant VCP, suggests that VCP dysfunc-
tion may play a role in TDP-43 aggregation.
TDP-43 contains RNA binding motifs that may be associated
with its function. Interestingly, another hereditary IBM,
oculopharyngeal muscular dystrophy, is caused by mutations
in another RNA binding protein, PABPN1.16 Mutant PABPN1
forms intranuclear inclusions that contain ubiquitin and
polyadenylated mRNA.17 It is not known whether a similar
process occurs with TDP-43 in sIBM and IBMPFD.
Diseases that develop TDP-43 inclusions include FTD-U, ALS,
IBMPFD and sIBM,1 17 suggesting that similar pathogenic
Figure 2 (A) Sporadic inclusion body myositis (sIBM) tissue from patients, immunostained with anti-TAR DNA binding protein-43 (TDP-43) (brown)
and counterstained with Congo red to allow visualisation of nuclei and myofibres. TDP-43 inclusions are small, in angular fibres and occasionally
surround rimmed vacuoles. (B) Overlay of sIBM patient biopsy immunostained with TDP-43 (red) and FK2, for ubiquitinated proteins (green). TDP-43
inclusions do not colocalise with ubiquitin. (C) sIBM patient tissue co-immunostained with anti-TDP-43 (red) and anti-CD8 (green at focal sites of
inflammation). Note the colocalisation of TDP-43 and CD8. This is in contrast with an adjacent fibre (arrow) with sarcoplasmic TDP-43 inclusions that
does not co-localise with CD8. (D) Muscle tissue from sIBM, inclusion body myopathy, Paget’s disease of the bone and frontotemporal dementia
(IBMPFD) and normal patient biopsies were homogenised and separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. The
subsequent gel was transferred to nitrocellulose and immunoblotted with an antibody to TDP-43. Normal tissue has a discrete band at 43 kDa
consistent with TDP-43, while sIBM and IBMPFD have a more prominent band and also a higher migrating band. Myosin is show as a loading control.
All tissues are from flash frozen biopsies except the lane noted with an asterisk which is from autopsy muscle. All bands are from the same
autoradiograph and moved for presentation purposes.
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mechanisms may be present. Additional studies will be
needed to further define the role of these proteins and their
dysregulation in central nervous system and skeletal muscle
tissue.
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